Phase 2 N=32 A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 27; 18; 20; 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Primary: Change in Soluble Vascular Cell Adhesion Molecule-1 (sVCAM) — -3.2; 4.17 ng/mL
N/A N=112 Sickle Cell Anemia WE CARE
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
Phase 2 N=15 Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Safety as Measured by the Number of Participants With Adverse Events — 9 participants
Phase 1 N=4 A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
Phase 3 N=30 Stem Cell Transplantation for Sickle Cell Anemia
Sickle Cell Disease
Primary: Number of Participants With Graft Failure — 3 Participants
Early Phase 1 N=17 A Dose-Finding Study of AG-348 in Sickle Cell Disease
Sickle Cell Disease
Primary: Number Participants With Most Common Reported Drug Related Adverse Events — 6; 3; 3 Participants
Phase 2 N=95 Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
Sickle Cell Disease
Primary: Percentage of Participants With Two-Year Post-Transplant Event Free Survival (EFS) — 88.0; 79.3 Percentage of Participants
Phase 2 N=17 Hydroxyurea and EPO in Sickle Cell Disease
Anemia, Sickle Cell · Sickle Cell Disease
Primary: Percentage of Participants With Hemoglobin (Hb) Response — 15 Participants
Phase 2 N=10 Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
Sickle Cell Disease
Primary: Fetal Hemoglobin Level — 8.3 Percentage
Phase 2 N=10 Decitabine for High-Risk Sickle Cell Disease
Neutropenia · Sickle Cell Disease
Primary: The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study. — 1; 1; 6 Participants
Phase 2 N=46 Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Sickle Cell Disease
Primary: Mean Change in the Plasma Soluble P-selectin Level — 0.74; 0.10 ng/ml — p=0.64
Phase 2 N=22 Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
Sickle Cell Disease
Primary: Event -Free Survival Rate — 19 Participants
Phase 2 N=96 A Phase II Trial of Regadenoson in Sickle Cell Anemia
Sickle Cell Anemia
Primary: Number of Participants With a Reduction in Invariant Natural-Killer T-Cell (iNKT Cell) Activation by 70% or More — 21; 10 Participants
Phase 2 N=27 Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)
Sickle Cell Disease
Primary: SS RBC Adhesion (Epi -1d/cm2- vs. Sham) by Treatment — 0; -0.3; 7.4; 2.7 Percentage of total RBC
N/A N=237 Preventing Acute Chest Syndrome by Transfusion Feasibility Study
Sickle Cell Disease
Primary: Acute Chest Syndrome — 11; 11; 22; 85 participants
Phase 1 N=15 Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients
Sickle Cell Disease
Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants
Phase 2 N=100 A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Sickle Cell Disease
Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 12; 24; 18; 23 Participants
Phase 2 N=198 Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
Sickle Cell Disease
Primary: Annual Rate of Sickle Cell-related Pain Crises (SCPC) Per Hodges-Lehmann Median — 1.63; 2.01; 2.98 SCPC per year — p== 0.010
Phase 2 N=30 Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)
Sickle Cell Disease
Primary: Percentage of Participants With Event-Free Survival (EFS) — 76; 69 percentage of participants
Phase 3 N=241 A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Sickle Cell Disease · Vaso-occlusive Pain Episode in Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Rate of Vaso-occlusive Crises (VOCs) [Adjudicated] Through Week 48 — 1.49; 1.58 Events per 48 weeks — p=0.6967
Phase 2 N=44 Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Maximum Plasma Concentration — 0.5835; 0.7425; 0.2186; 0.7128 ng/mL
Phase 1 N=30 Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Phase 1 Sickle Cell
Primary: Number of Participants With Potentially Clinically Important (PCI) Change From Baseline in Vital Signs — 0; 0; 0; 2 participants
Phase 1 N=39 Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT
Phase 2 N=62 Prasugrel Versus Placebo in Adult Sickle Cell Disease
Sickle Cell Anemia
Primary: Percentage of Participants With Hemorrhagic Events Requiring Medical Intervention During the Treatment Duration — 0; 0 percentage of participants
Phase 2 N=29 Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Phase 4 N=140 An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Sickle Cell Disease (SCD)
Primary: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) — 3; 3 Participants
Phase 2 N=12 Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
Sickle Cell Disease · Stroke
Primary: Number of Randomized Participants With Central Nervous System Complications — 1; 4 Participants — p=0.2914
Phase 1 N=11 Aspirin Prophylaxis in Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Serious Adverse Events — 6; 9; 0; 0 events
N/A N=120 Decision Aid for Therapeutic Options In Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia · Hemoglobin SS
Primary: Acceptability of Decision Aid Education Assessed by the Acceptability Survey — 3; 3; 3; 3 units on a scale